EUCTR2007-001286-15-HU进行中（未招募）不适用
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) who have failed or are intolerant to tyrosine kinase inhibitor therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 81
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients, age 18 years or older
- •2.Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in either chronic, accelerated, or blast phase.
- •a)Patients in accelerated phase will meet one or more of the following criteria: >=15% - <30% blasts in peripheral blood or bone marrow, >=30% blasts + promyelocytes in peripheral blood or bone marrow, >=20% basophils in peripheral blood or bone marrow; platelet count <100 x 10^9/L unrelated to therapy or clonal evolution.
- •b)CML in blast phase will be defined as >=30% blasts in the bone marrow or presence of extramedullary disease.
- •c)All other patients will be considered to have chronic phase CML
- •3.Patients will have either failed, demonstrated intolerance, or a combination of prior failure and intolerance, to prior treatments with at least two tyrosine kinase inhibitors (TKI's). failure of TKI treatment may either be primary (never achieved a response) or secondary resistance (loss of response).
- •TKI treatment failure will be defined as one of the following:
- •a) No complete hematologic response (CHR) by 12 weeks (whether lost or never achieved)
- •b) No cytogenetic response by 24 weeks (i.e., 100% Ph-positive) (whether lost or never achieved)
- •c) No major catogenetic response by 52 weeks (i.e., >=35% Ph-positive) (whether lost or never achieved)
- •d) Progressive leukocytosis: i) increasing white blood cell count on at least two consecutive evaluations, at least 2 weeks apart and doubling from the nadir to >= 20,000/uL or ii) absolute increase WBC by >= 50,000/uL above the post-tretment nadir
- •Intolerance to TKI therapy will be defined as one of the following:
- •a) Grade 3-4 non-hematologic toxicity that does not resolve with adequate intervention
- •b) Grade 4 hematologic toxicity lasting more than 7 days
- •c) Any Grade >= 2 toxicity that is unacceptable to the patient
- •4.Patients must have completed all previous anti-leukemic therapy for at least 2 weeks, prior to the first planned dose of HHT, except as noted below, and must have fully recovered from side effects of a previous therapy, unless disease progression necessitates early therapy, determined by the Principal Investigator or treating physician. In patients with rapidly proliferating disease, hydroxyurea may be administered during the first two cycles of treatment, if clinically indicated, to control disease. In such cases, complete hematologic response (CHR) must be sustained for >= 4 weeks for accelerated and blast phase CML and for >= 8 weeks for chronic phase CML, following the discontinuation of hydroxyurea, to be considered as a CHR. Patients may receive anagrelide for up to 28 days (in countries where the product is registered). Leukapheresis is allowed up to 24 hours prior to the first treatment cycle with HHT.
- •5.Bilirubin = 2.0 times upper limit of normal (ULN)
- •ALT = 3 times ULN
- •Creatinine = 1.5 times ULN
- •6.ECOG performance status 0-2.
- •7. Be able to comply with the requirements of the entire study.
- •8. Be able and willing to provide written informed consent prior to any study related procedure. (In the event that the patient is re-screened for study participation or a protocol amendment alters the care of an ongoing patient, a new informed consent form must be signed.)
- •9. Sexually active patients and their partners must use an effective double barrier method of contraception associated with a low failure rate (i.e. less than 1% per year) during and for six mont
排除标准
- •1.NYHA class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia and requiring therapy, uncontrolled hypertension or congestive heart failure.
- •2.Myocardial infarction in the previous 12 weeks.
- •3.Other concurrent illness which would preclude study conduct and assessment, including but not limited to another active malignancy (excluding squamous or basal cell skin cancer and in situ cervical cancer), uncontrolled and active infection, positive HIV status or positive HTLV I/II status, whether on treatment or not.
- •4.Pregnant or lactating.
- •5.Any medical or psychiatric condition, which may compromise the ability to give written informed consent or to comply with the study protocol.
- •6.Lymphoid Ph+ blast crisis
- •7. Patient is enrolled in another clinical inverstigation within 30 days of enrollment or is receiving another investigational agent
- •Patients excluded for any of the aforementioned reasons may be re-screened for participation at any time if the exclusion characteristic has changed, or is likely to change, and after consultation with the Principal Investigator and the Sponsor.
研究者
相似试验
进行中（未招募）
1 期
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) who have failed or are intolerant to tyrosine kinase inhibitor therapyEUCTR2007-001286-15-FRStragen France81
进行中（未招募）
不适用
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Refractory or Relapsed Acute Myeloid Leukemia (AML)EUCTR2006-004517-17-FRStragen France
已完成
2 期
Open Label Study of Subcutaneous Omacetaxine in Patients With Advanced Chronic Myeloid Leukemia.ACTRN12609000377235ChemGenex Pharmaceuticals Inc.100
已完成
2 期
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene MutatioCTRI/2013/06/003748ChemGenex Pharmaceuticals now Teva Pharmaceutical Industries Ltd100
进行中（未招募）
不适用
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene MutatioEUCTR2006-000176-32-HUStragen France81